

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 48

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 48

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 48

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:*Recommended INN Chemical name or description; Molecular formula; Graphic formula**DCI Recommandée Nom chimique ou description; Formule brute; Formule développée**DCI Recomendada Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada***acolbifenum**

acolbifene


(+)-(2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-2H-1-benzopyran-7-ol

acolbifène

(+)-(2S)-3-(4-hydroxyphényl)-4-méthyl-2-[4-[2-(pipéridin-1-yl)éthoxy]phényl]-2H-1-benzopyran-7-ol

acolbifeno

(+)-(2S)-3-(4-hidroxifenil)-4-metil-2-[4-[2-(piperidin-1-il)etoxi]fenil]-2H-1-benzopiran-7-ol

 $C_{29}H_{31}NO_4$ **asoprisnilum**

asoprisnil


11β-[4-[(E)-(hydroxyimino)methyl]phenyl]-17β-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one

asoprisnil

11β-[4-[(E)-(hydroxyimino)méthyl]phényl]-17β-méthoxy-17-(méthoxyméthyl)estra-4,9-dién-3-one


asoprisnilo

11β-[4-[(E)-(hidroxiimino)metil]fenil]-17β-metoxi-17-(metoximetil)estra-4,9-dien-3-ona



 $C_{28}H_{35}NO_4$ 

atomoxetinum


atomoxetine	(-)-(3 <i>R</i>)- <i>N</i> -methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
atomoxétine	(-)-(3 <i>R</i>)- <i>N</i> -méthyl-3-(2-méthylphénoxy)-3-phénylpropan-1-amine
atomoxetina	(-)-(3 <i>R</i>)-3-fenil- <i>N</i> -metil-3-(2-metilfenoxi)propan-1-amina

**bazedoxifenum**

bazedoxifene	1-[4-[2-(hexahydro-1 <i>H</i> -azepin-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1 <i>H</i> -indol-5-ol
bazédoxifène	1-[4-[2-(hexahydro-1 <i>H</i> -azépin-1-yl)éthoxy]benzyl]-2-(4-hydroxyphényl)-3-méthyl-1 <i>H</i> -indol-5-ol
bazedoxifeno	1-[4-[2-(hexahidro-1 <i>H</i> -azepin-1-il)etoxi]bencil]-2-(4-hidroxifenil)-3-metil-1 <i>H</i> -indol-5-ol

**bifarceptum**

bifarcept	interferon α/β receptor (human isoform p40 precursor)
bifarcept	précurseur de la partie soluble de la chaîne 2 du récepteur humain de type I de l'interféron α et β
bifarcept	precursor de la fracción soluble de la cadena 2 del receptor humano de tipo I del interferón α y β



MLLSQNAFIV	RSLNLVLMVY	ISLVFGISYD	SPDYTDESCT
FKISLRNFRS	ILSWELKNHS	IVPTHYTLLY	TIMSKPEDLK
VVKNCANTTR	SFCDLTDEWR	STHEAYVTVL	EGFSGNTTLF
SCSHNFWLAI	DMSFEPPEFE	IVGFTNHINV	MVKFPSIVEE
ELQFDLSLVI	EEQSEGIVKK	HKPEIKGNMS	GNFTYIIDKL
IPNTNYCVSV	YLEHSDEQAV	IKSPLKCTLL	PPGQESEFS

coluracetamum

coluracetam



N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-*b*]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide

coluracétam

N-(2,3-diméthyl-5,6,7,8-tétrahydrofuro[2,3-*b*]quinoléin-4-yl)-2-(2-oxopyrrolidin-1-yl)acétamide

coluracetam

N-(2,3-dimetil-5,6,7,8-tetrahidrofuro[2,3-*b*]quinolin-4-il)-2-(2-oxopirrolidin-1-il)acetamida

**dapivirinum**

dapivirine


4-[[4-[(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl]amino]benzonitrile

dapivirine

4-[[4-[(2,4,6-triméthylphényl)amino]pyrimidin-2-yl]amino]benzonitrile

dapivirina

4-[[4-[(2,4,6-trimetilfenil)amino]pirimidin-2-il]amino]benzonitrilo



deferasiroxum



deferasirox

4-[3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl]benzoic acid

déférasirox

acide 4-[3,5-bis(2-hydroxyphényl)-1*H*-1,2,4-triazol-1-yl]benzoïque

deferasirox

ácido 4-[3,5-bis(2-hidroxifenil)-1*H*-1,2,4-triazol-1-il]benzoico**degarelixum**

degarelix


N-acetyl-3-(naphtalen-2-yl)-*D*-alanyl-4-chloro-*D*-phenylalanyl-3-(pyridin-3-yl)-*D*-alanyl-*L*-seryl-4-[[[(4*S*)-2,6-dioxohexahydropyrimidin-4-yl]carbonyl]amino]-*L*-phenylalanyl-4-(carbamoylamino)-*D*-phenylalanyl-*L*-leucyl-*N*⁶-(1-methylethyl)-*L*-lysyl-*L*-prolyl-*D*-alaninamide

degarélix

acétyl-[3-(naphtalén-2-yl)-*D*-alanyl]-(4-chloro-*D*-phénylalanyl)-[3-(pyridin-3-yl)-*D*-alanyl]-*L*-séryl-[4-[[[(4*S*)-2,6-dioxohexahydropyrimidin-4-yl]carbonyl]amino]-*L*-phénylalanyl]-[4-(carbamoylamino)-*D*-phénylalanyl]-*L*-leucyl-[*N*⁶-(1-méthyléthyl)-*L*-lysyl]-*L*-prolyl-*D*-alaninamide

degarelix

[*N*-acetil-3-(naftalen-2-il)-*D*-alanil]-(4-cloro-*D*-fenilalanil)-[3-(piridin-3-il)-*D*-alanil]-*L*-seril-[4-[[[(4*S*)-2,6-dioxohexahidropirimidin-4-il]carbonil]amino]-*L*-fenilalanil]-[4-(carbamoilamino)-*D*-fenilalanil]-*L*-leucil-[*N*⁶-(1-metiletil)-*L*-lisil]-*L*-proliil-*D*-alaninamida



dersalazinum

dersalazine



2-hydroxy-5-[[4-[(1*Z*)-3-[4-[(2-methyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)methyl]piperidin-1-yl]-3-oxo-1-phenylprop-1-enyl]phenyl]diazényl]benzoic acid

dersalazine

acide 2-hydroxy-5-[[4-[(1*Z*)-3-[4-[(2-méthyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)méthyl]pipéridin-1-yl]-3-oxo-1-phénylprop-1-ényl]phényl]diazényl]benzoïque

dersalazina

ácido 2-hidroxi-5-[[4-[(1*Z*)-3-[4-[(2-metil-1*H*-imidazo[4,5-*c*]piridin-1-il)metil]piperidin-1-il]-3-oxo-1-fenilprop-1-enil]fenil]diazenil]benzoico

**detivicioclovirum**

detivicioclovir


2-[(2-amino-9*H*-purin-9-yl)methyl]propane-1,3-diol

détivicioclovir

2-[(2-amino-9*H*-purin-9-yl)méthyl]propane-1,3-diol

detivicioclovir

2-[(2-amino-9*H*-purin-9-il)metil]propano-1,3-diol

**edonentanum**

edonentan



N-[[2'-[(4,5-dimethylisoxazol-3-yl)sulfamoyl]-4-(oxazol-2-yl)biphenyl-2-yl]methyl]-*N*,3,3-trimethylbutanamide

édonentan

N-[[2'-[(4,5-diméthylisoxazol-3-yl)sulfamoyl]-4-(oxazol-2-yl)biphényl-2-yl)méthyl]-*N*,3,3-triméthylbutanamide

edonentán

N-[[2'-[(4,5-dimetilisoxazol-3-il)sulfamoil]-4-(oxazol-2-il)bifenil-2-il]metil]-*N*,3,3-trimetilbutanamida

**efaproxiralum**

efaproxiral


2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid

éfaproxiral

acide 2-[4-[2-[(3,5-diméthylphényl)amino]-2-oxoéthyl]phénoxy]-2-méthylpropanoïque

efaproxiral

ácido 2-[4-[2-[(3,5-dimetilfenil)amino]-2-oxoetil]fenoxi]-2-metilpropanoico

**fadolmidinum**

fadolmidine


3-(imidazol-4-ylmethyl)-5-indanol

fadolmidine

(3*RS*)-3-[(1*H*-imidazol-4-yl)méthyl]-2,3-dihydro-1*H*-indén-5-ol

fadolmidina

3-(imidazol-4-ilmetil)-5-indanol




flindokalnerum

flindokalner (3*S*)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2*H*-indol-2-one

flindokalner (3*S*)-3-(5-chloro-2-méthoxyphényl)-3-fluoro-6-(trifluorométhyl)-1,3-dihydro-2*H*-indol-2-one



flindokalner (3*S*)-3-(5-cloro-2-metoxifenil)-3-fluoro-6-(trifluorometil)-1,3-dihidro-2*H*-indol-2-ona

**gimatecanum**

gimatecan (4*S*)-11-[(*E*)-[(1,1-dimethylethoxy)imino]methyl]-4-ethyl-4-hydroxy-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*)-dione

gimatécan (4*S*)-11-[(*E*)-[(1,1-diméthyléthoxy)imino]méthyl]-4-éthyl-4-hydroxy-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione


gimatecán (4*S*)-11-[(*E*)-[(1,1-dimetiletoxi)imino]metil]-4-etil-4-hidroxi-1,12-dihidro-14*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-3,14(4*H*)-diona

**icaridinum**

icaridin 1-methylpropyl 2-(2-hydroxyethyl)piperidine-1-carboxylate

icaridine 2-(2-hydroxyéthyl)pipéridine-1-carboxylate de 1-méthylpropyle

icaridina 2-(2-hidroxietil)piperidina-1-carboxilato de sec-butilo



iguratimodum


iguratimod

N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4*H*-1-benzopyran-3-yl]formamide

iguratimod

N-[7-[(méthylsulfonyl)amino]-4-oxo-6-phénoxy-4*H*-1-benzopyran-3-yl]formamide

iguratimod

N-[7-[(metilsulfonil)amino]-4-oxo-6-fenoxi-4*H*-1-benzopiran-3-il]formamida $C_{17}H_{14}N_2O_6S$ **ilaprazolum**


ilaprazole

2-[(*RS*)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-5-(1*H*-pyrrol-1-yl)-1*H*-benzimidazole

ilaprazole

2-[(*RS*)-[(4-méthoxy-3-méthylpyridin-2-yl)méthyl]sulfinyl]-5-(1*H*-pyrrol-1-yl)-1*H*-benzimidazole

ilaprazol

2-[(*RS*)-[(4-metoxi-3-metilpiridin-2-il)metil]sulfinil]-5-(1*H*-pirrol-1-il)-1*H*-bencimidazol $C_{19}H_{18}N_4O_2S$ and enantiomer
et énantiomère
y enantiómero

indiplonum


indiplon

N-methyl-*N*-[3-[3-(thiophen-2-ylcarbonyl)pyrazolo[1,5-*a*]pyrimidin-7-yl]phenyl]acetamide

indiplone

N-méthyl-*N*-[3-[3-(thiophén-2-ylcarbonyl)pyrazolo[1,5-*a*]pyrimidin-7-yl]phényl]acétamide

indiplón

N-metil-*N*-[3-[3-(tiofen-2-ilcarbonyl)pirazolo[1,5-*a*]pirimidin-7-il]fenil]acetamida $C_{20}H_{16}N_4O_2S$ **indisulamum**


indisulam

N-(3-chloro-1*H*-indol-7-yl)benzene-1,4-disulfonamide

indisulam

N-(3-chloro-1*H*-indol-7-yl)benzène-1,4-disulfonamide

indisulam

N-(3-cloro-1*H*-indol-7-il)benceno-1,4-disulfonamida $C_{14}H_{12}ClN_3O_4S_2$ **leconotidum**

leconotide


omega-conopeptide MVIIA

léconotide

conopeptide MVIIA oméga


leconotida

conopéptido MVIIA omega


 $C_{107}H_{179}N_{35}O_{36}S_7$ 



licofelonum

licofelone	[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1 <i>H</i> -pyrrolizin-5-yl]acetic acid
licofélone	acide [6-(4-chlorophényl)-2,2-diméthyl-7-phényl-2,3-dihydro-1 <i>H</i> -pyrrolizin-5-yl]acétique
licofelona	ácido [6-(<i>p</i> -clorofenil)-7-fenil-2,2-dimetil-2,3-dihidro-1 <i>H</i> -pirrolizin-5-il]acético
	$C_{23}H_{22}ClNO_2$

**lonafarnibum**

lonafarnib	(+)-4-[2-[4-[(11 <i>R</i>)-3,10-dibromo-8-chloro-6,11-dihydro-5 <i>H</i> -benzo[5,6]cyclohepta[1,2- <i>b</i>]pyridin-11-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
lonafarnib	(+)-4-[2-[4-[(11 <i>R</i>)-3,10-dibromo-8-chloro-6,11-dihydro-5 <i>H</i> -benzo[5,6]cyclohepta[1,2- <i>b</i>]pyridin-11-yl]pipéridin-1-yl]-2-oxoéthyl]pipéridine-1-carboxamide
lonafarnib	(+)-4-[2-[4-[(11 <i>R</i>)-3,10-dibromo-8-cloro-6,11-dihidro-5 <i>H</i> -benzo[5,6]ciclohepta[1,2- <i>b</i>]piridin-11-il]piperidin-1-il]-2-oxoetil]piperidina-1-carboxamida
	$C_{27}H_{31}Br_2ClN_4O_2$




lubazodonumlubazodone (2*S*)-2-[[[(7-fluoro-2,3-dihydro-1*H*-inden-4-yl)oxy]methyl]morpholinelubazodone (2*S*)-2-[[[(7-fluoro-2,3-dihydro-1*H*-indén-4-yl)oxy]méthyl]morpholinelubazodona (2*S*)-2-[[[(7-fluoro-2,3-dihidro-1*H*-inden-4-il)oxi]metil]morfolina**luliconazolum**luliconazole (-)-(E)-[(4*R*)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene](1*H*-imidazol-1-yl)acetonitrileluliconazole (-)-(E)-[(4*R*)-4-(2,4-dichlorophényl)-1,3-dithiolan-2-ylidène](1*H*-imidazol-1-yl)acétonitrileluliconazol (-)-(E)-[(4*R*)-4-(2,4-diclorofenil)-1,3-ditiolan-2-ilideno](1*H*-imidazol-1-il)acetonitrilo**meldonium**

meldonium 3-(2,2,2-trimethyldiazaniumyl)propanoate

meldonium 3-(2,2,2-triméthyldiazaniumyl)propanoate

meldonio 3-(2,2,2-trimetildiazanioil)propanoato



metelimumabum

metelimumab

immunoglobulin G4, anti-(human transforming growth factor β 1) (human monoclonal CAT-192 γ 4-chain), disulfide with human monoclonal CAT-192 κ -chain, dimer

mételimumab

immunoglobuline G4, anti-(facteur de croissance transformant humain β 1) (chaîne γ 4 de l'anticorps monoclonal humain CAT-192), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain CAT-192

metelimumab

immunoglobulina G4, anti-(factor de crecimiento transformador humano β 1) (cadena γ 4 del anticuerpo monoclonal humano CAT-192), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano CAT-192

mitemcinalum

mitemcinal



8,9-didehydro-*N*-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-*O*-methyl-*N*-(1-methylethyl)-11-oxoerythromycin

mitemcinal

(2*S*,4*R*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-9-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl- α -*L*-ribo-hexopyranosyl)oxy]-5-éthyl-4-méthoxy-2,4,8,10,12,14-hexaméthyl-11-[[3,4,6-tridésoxy-3-[méthyl(1-méthyléthyl)amino]- β -*D*-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadéc-1(14)-ène-3,7-dione

mitemcinal

(2*S*,4*R*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-9-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil- α -*L*-ribo-hexopiranosil)oxil]-5-etil-4-metoxi-2,4,8,10,12,14-hexametil-11-[[3,4,6-tridesoxi-3-[metil(1-metiletil)amino]- β -*D*-xilo-hexopiranosil]oxil]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-eno-3,7-diona





naxifyllinum

naxifylline 8-[(1*S*,2*R*,4*S*,5*S*,6*S*)-3-oxatricyclo[3.2.1.0^{2,4}]oct-6-yl]-1,3-dipropyl-3,7-dihydro-1*H*-purine-2,6-dione

naxifylline 8-[(1*S*,2*R*,4*S*,5*S*,6*S*)-3-oxatricyclo[3.2.1.0^{2,4}]oct-6-yl]-1,3-dipropyl-3,7-dihydro-1*H*-purine-2,6-dione



naxifilina 8-[(1*S*,2*R*,4*S*,5*S*,6*S*)-3-oxatriciclo[3.2.1.0^{2,4}]oct-6-il]-1,3-dipropil-3,7-dihidro-1*H*-purina-2,6-diona

**oglufanidum**

oglufanide L- α -glutamyl-L-tryptophan

oglufanide L- α -glutamyl-L-tryptophane



oglufanida L- α -glutamyl-L-triptófano

**olcegepantum**

olcegepant *N*-[(1*R*)-2-[[[(1*S*)-5-amino-1-[[4-(pyridin-4-yl)piperazin-1-yl]carbonyl]pentyl]amino]-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl]-4-(2-oxo-1,4-dihydroquinazolin-3(2*H*)-yl)piperidine-1-carboxamide

olcégépant *N*-[(1*R*)-2-[[[(1*S*)-5-amino-1-[[4-(pyridin-4-yl)pipérazin-1-yl]carbonyl]pentil]amino]-1-(3,5-dibromo-4-hidroxybenzil)-2-oxoéthil]-4-(2-oxo-1,4-dihidroquinazolin-3(2*H*)-yl)pipéridine-1-carboxamide

olcegepant *N*-[(1*R*)-2-[[[(1*S*)-5-amino-1-[[4-(piridin-4-il)piperazin-1-il]carbonil]pentil]amino]-1-(3,5-dibromo-4-hidroxi-bencil)-2-oxoetil]-4-(2-oxo-1,4-dihidroquinazolin-3(2*H*)-il)piperidina-1-carboxamida

**oregovomabum**

oregovomab

immunoglobulin G1, anti-(human CA125 (carbohydrate antigen)) (mouse monoclonal B43.13 γ 1-chain), disulfide with mouse monoclonal B43.13 κ -chain, dimer

orégovomab

immunoglobuline G1, anti-(antigène osidique humain CA125) (chaîne γ 1 de l'anticorps monoclonal de souris B43.13), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris B43.13

oregovomab

immunoglobulina G1, anti-(antígeno osídico humano CA125) (cadena γ 1 del anticuerpo monoclonal de ratón B43.13), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón B43.13

otamixabanum

otamixaban



methyl (2*R*,3*R*)-2-(3-carbamimidoylbenzyl)-3-[[4-(1-oxidopyridin-4-yl)benzoyl]amino]butanoate

otamixaban

(2*R*,3*R*)-2-(3-carbamimidoylbenzyl)-3-[[4-(1-oxypyridin-4-yl)benzoyl]amino]butanoate de méthyle


otamixabán

(2*R*,3*R*)-2-(3-carbamimidoilbencil)-3-[[4-(1-oxidopiridin-4-il)benzoil]amino]butanoato de metilo



paliferminum



palifermin	[23-methionine]-23-163-fibroblast growth factor 7 (human clone 32/49 reduced)
palifermine	[23-méthionine]-23-163-facteur 7 de croissance du fibroblaste, protéine réduite produite par le clone humain 32/49
palifermina	[23-metionina]-23-163-factor 7 de crecimiento de fibroblastos, proteína reducida producida por el clon humano 32/49



MSYDMEGGD	IRVRRLFCRT	QWYLRIDKRG	KVKGQTQEMKN
NYNIMEIRTV	AVGIVAIGKV	ESEFYLAMNK	EGKLYAKKEC
NEDCNFKELI	LENHYNTYAS	AKWTHNGGEM	FVALNQKGIP
VRGKKTKEQ	KTAHFLPMAI	T	

peramivirum

peramivir	(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i>)-3-[(1 <i>S</i>)-1-(acetylamino)-2-ethylbutyl]-4-(carbamimidoylamino)-2-hydroxycyclopentanecarboxylic acid
péramivir	acide (1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i>)-3-[(1 <i>S</i>)-1-(acétylamino)-2-éthylbutyl]-4-(carbamimidoylamino)-2-hydroxycyclopentanecarboxylique
peramivir	ácido (1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i>)-3-[(1 <i>S</i>)-1-(acetilamino)-2-etilbutil]-4-(carbamimidoilamino)-2-hidroxiciclopentanocarboxílico



talibegronum


talibegron

[4-[2-[[[(2*R*)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid

talibégron

acide [4-[2-[[[(2*R*)-2-hydroxy-2-phényléthyl]amino]éthoxy]phényl]acétique

talibegrón

ácido [4-[2-[[[(2*R*)-2-hidroxi-2-feniletil]amino]etoxi]fenil]acético $C_{18}H_{21}NO_4$ **tariquidarum**


tariquidar

N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide

tariquidar

N-[2-[[4-[2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-2(1*H*)-yl)éthyl]phényl]carbamoyle]-4,5-diméthoxyphényl]quinoléine-3-carboxamide

tariquidar

N-[2-[[4-[2-(6,7-dimetoxi-3,4-dihidroisoquinolin-2(1*H*)-il)etil]fenil]carbamoil]-4,5-dimetoxifenil]quinolina-3-carboxamida $C_{38}H_{38}N_4O_6$ **tebaniclinum**


tebanicline

5-[(2*R*)-azetidin-2-ylmethoxy]-2-chloropyridine

tebanicline

5-[(2*R*)-azétidin-2-ylméthoxy]-2-chloropyridine

tebaniclina


5-[(2*R*)-azetidin-2-ilmetoxi]-2-cloropiridina $C_9H_{11}ClN_2O$ 

tecastemizolum

tecastemizole 1-(4-fluorobenzyl)-*N*-(piperidin-4-yl)-1*H*-benzimidazol-2-amine

técastémizole 1-(4-fluorobenzyl)-*N*-(pipéridin-4-yl)-1*H*-benzimidazol-2-amine

tecastemizol 1-(4-fluorobencil)-*N*-(piperidin-4-il)-1*H*-bencimidazol-2-amina

**technetium (^{99m}Tc) fanolesomabum**

technetium (^{99m}Tc) fanolesomab immunoglobulin M, anti-(human CD15 antigen) (mouse monoclonal RB5 μ-chain), disulfide with mouse monoclonal RB5 light chain, pentamer, [^{99m}Tc]technetium salt

technétium (^{99m}Tc) fanolésomab immunoglobuline M, anti-(antigène CD15 humain) (chaîne μ de l'anticorps monoclonal de souris RB5), pentamère du disulfure de la chaîne légère de l'anticorps monoclonal de souris RB5, sel de [^{99m}Tc]technétium



tecnecio (^{99m}Tc) fanolesomab inmunoglobulina M, anti-(antígeno CD15 humano) (cadena μ del anticuerpo monoclonal de ratón RB5), pentámero del disulfuro de la cadena ligera del anticuerpo monoclonal de ratón RB5, sal de [^{99m}Tc]tecnecio

tigecyclinum

tigecycline (4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(dimethylamino)-9-[[[(1,1-diméthyléthyl)amino]acétyl]amino]-3,10,12,12*a*-tetrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

tigécycline (4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(diméthylamino)-9-[[[(1,1-diméthyléthyl)amino]acétyl]amino]-3,10,12,12*a*-tétrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

tigeciclina (4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(dimetilamino)-9-[[[(1,1-dimetiletil)amino]acetil]amino]-3,10,12,12*a*-tetrahidroxi-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahidrotetraceno-2-carboxamida

**tiviciclovirum**


tiviciclovir

2-amino-9-[3-hydroxy-2-(hydroxymethyl)propyl]-1,9-dihydro-6*H*-purin-6-one

tiviciclovir

2-amino-9-[3-hydroxy-2-(hydroxyméthyl)propyl]-1,9-dihydro-6*H*-purin-6-one

tiviciclovir

2-amino-9-[3-hidroxi-2-(hidroximetil)propil]-1,9-dihidro-6*H*-purin-6-ona**tosagestinum**

tosagestin


17-hydroxy-11-methylene-19-nor-17α-pregna-4,15-dien-20-yn-3-one

tosagestin

17-hydroxy-11-méthylène-19-nor-17α-prègna-4,15-dién-20-yn-3-one

tosagestina

17-hidroxi-11-metilen-19-nor-17α-pregna-4,15-dien-20-in-3-ona



trabectedinum

trabectedin



(1'*R*,6*R*,6*aR*,7*R*,13*S*,14*S*,16*R*)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro[6,16-(epithiopropanooxymethano)-7,13-imino-6*aH*-1,3-dioxolo[7,8]isoquino[3,2-*b*][3]benzazocine-20,1'(2'*H*)-isoquinolin]-5-yl acetate

trabectédine

acétate de (1'*R*,6*R*,6*aR*,7*R*,13*S*,14*S*,16*R*)-6',8,14-trihydroxy-7',9-diméthoxy-4,10,23-triméthyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro[6,16-(épithiopropanooxyméthano)-7,13-imino-6*aH*-1,3-dioxolo[7,8]isoquino[3,2-*b*][3]benzazocine-20,1'(2'*H*)-isoquinoléin]-5-yle

trabectedina

acetato de (1'*R*,6*R*,6*aR*,7*R*,13*S*,14*S*,16*R*)-6',8,14-trihidroxi-7',9-dimetoxi-4,10,23-trimetil-19-oxo-3',4',6,7,12,13,14,16-octahidrospiro[6,16-(epitiopropanooximetano)-7,13-imino-6*aH*-1,3-dioxolo[7,8]isoquino[3,2-*b*][3]benzazocina-20,1'(2'*H*)-isoquinolin]-5-ilo

**zosuquidarum**

zosuquidar



(2*R*)-1-[4-[(1*aR*,6*r*,10*bS*)-1,1-difluoro-1,1*a*,6,10*b*-tetrahydrodibenzo[*a,e*]cyclopropa[*c*]cyclohepten-6-yl]piperazin-1-yl]-3-(quinolin-5-yloxy)propan-2-ol

zosuquidar

(2*R*)-1-[4-[(1*aR*,6*r*,10*bS*)-1,1-difluoro-1,1*a*,6,10*b*-tétrahydrodibenzo[*a,e*]cyclopropa[*c*]cycloheptén-6-yl]pipérazin-1-yl]-3-(quinoléin-5-yloxy)propan-2-ol

zosuquidar

(2*R*)-1-[4-[(1*aR*,6*r*,10*bS*)-1,1-difluoro-1,1*a*,6,10*b*-tetrahydrodibenzo[*a,e*]ciclopropa[*c*]ciclohepten-6-il]piperazin-1-il]-3-(quinolin-5-iloxi)propan-2-ol



**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Prop. INN): List 40
Dénominations communes internationales recommandées (DCI Prop.): Liste 40
Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 40
(WHO Drug Information, Vol. 12, No. 2, 1998)

- | | |
|--|--|
| p. 177 <i>suprimase</i>
efavirenzo | <i>insértese</i>
efavirenz |
| p. 187 <i>suprimase</i>
moxifloxacina | <i>insértese</i>
moxifloxacino |
| p. 200 technetii (^{99m}Tc) apcitidum
tecnecio (^{99m} Tc) apcitida | <i>sustituyase la descripción por la siguiente:</i>
hidrógeno [N-(mercaptoacetil)-D-tirosil-S-(3-aminopropil)-L-cisteinilglicil-L-α-aspartil-L-cisteinilglicilglicil-S-(acetamidometil)-L-cisteinilglicil-S-(acetamidometil)-L-cisteinilglicilglicil-L-cisteinamida (1→5)-sulfuro cíclico (5-)-N ¹¹ ,N ¹² ,N ¹³ ,S ¹³]oxo[^{99m} Tc]tecnetato(V) de sodio |
| p. 202 tobicillinum
tobicillina | <i>sustituyase la descripción por la siguiente:</i>
(2S,5R,6R)-3,3-dimetil-7-oxo-6-(2-fenilacetamido)-4-tia-1-azabicyclo-[3.2.0]heptano-2-carboxilato de α-hidroxi-m-tolilo, isobutirato (éster) |
| p. 205 <i>suprimase</i>
clorprotixeno | <i>insértese</i>
clorprotixeno |

Recommended International Nonproprietary Names (Prop. INN): List 41
Dénominations communes internationales recommandées (DCI Prop.): Liste 41
Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 41
(WHO Drug Information, Vol. 13, No. 1, 1999)

- | | |
|---|--|
| p. 39 anatumomabum mafenatoxum
anatumomab mafenatox | <i>sustituyase la descripción por la siguiente:</i>
inmunoglobulina G1 (cadena γ1 del fragmento Fab del anticuerpo monoclonal humanizado de ratón, clon pMB125, dirigido contra la glicoproteína 72 humana asociada a tumores)-[227-alanina]enterotoxina A (<i>Staphylococcus aureus</i>) complejada con la cadena κ del anticuerpo monoclonal de ratón clon pMB125 |
| p. 46 <i>suprimase</i>
olamufloxacina | <i>insértese</i>
olamufloxacino |

p. 48 *suprimase* *insértese*
estansoporfina estansoporfina

p. 48 **stannsoportinum**
estansoporfina *sustituyase la descripción por la siguiente:*
(OC-6-13)-dicloro[7,12-dietil-3,8,13,17-tetrametilporfirina-2,18-dipropionato(4-)-*N*²¹,*N*²²,*N*²³,*N*²⁴]estannato(2-) de dihidrógeno

Recommended International Nonproprietary Names (Prop. INN): List 42

Dénominations communes internationales recommandées (DCI Prop.): Liste 42

Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 42
(WHO Drug Information, Vol. 13, No. 3, 1999)

p. 190 *suprimase* *insértese*
enrasentano enrasentán

p. 196 **minopafantum**
minopafant *sustituyase la descripción por la siguiente:*
(+) cloruro de 1-etil-2-[[*N*-[[[(2*R*)-2-metoxi-3-[[[4-[(octadecilcarbamoil)=oxi]piperidino]carbonil]oxi]propoxi]carbonil]-*o*-anisamido]metil]piridinio

p. 203 **tabimorelinum**
tabimorelina *sustituyase la descripción por la siguiente:*
(*R*)-α-[(*E*)-5-amino-*N*,5-dimetil-2-hexenamido]-*N*-metil-*N*-[(*R*)-α-(metilcarbamoil)fenetil]-2-naftalenopropionamida

p. 212 **sulesomabum**
sulesomab *sustituyase la descripción por la siguiente:*
inmunoglobulina G1, anti-(antígeno celular NCA-90 de granulocito humano) fragmento Fab' (cadena γ1 del anticuerpo monoclonal de ratón IMMU-MN3), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-MN3

p. 212 **technetium (^{99m}Tc) pintumomabum**
tecnecio (^{99m}Tc) pintumomab *sustituyase la descripción por la siguiente:*
sal de [^{99m}Tc]tecnecio de la inmunoglobulina G1 anti-(antígeno asociado a los adenocarcinomas humanos) (cadena γ1 del anticuerpo monoclonal de ratón 170), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón 170

p. 214 **igovomabum**
igovomab *sustituyase la descripción por la siguiente:*
inmunoglobulina G1, anti-[(antígeno osídico) CA 125 humano] (fragmento F(ab')2 (cadena γ1 del anticuerpo monoclonal de ratón OC125F(AB')2), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón OC125F(AB')2

Recommended International Nonproprietary Names (Prop. INN): List 43**Dénominations communes internationales recommandées (DCI Prop.): Liste 43****Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 43****(WHO Drug Information, Vol. 14, No. 1, 2000)****p. 46 cadrofloxacinum**

cadrofloxacin

remplacer la description par la suivante:

(-)-acide 1-cyclopropyl-8-(difluorométhoxy)-6-fluoro-7-[(3S)-3-méthylpipérazin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

p. 53 finrozolum


finrozole

*replace the description and the graphic formula by the following:**p-[(1RS,2SR)-3-(p-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile*

finrozole

*remplacer la description et la formule développée par la suivante:**4-[(1RS,2SR)-3-(4-fluorophényl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile*

finrozol

*sustituyase la descripción y la fórmula empírica por la siguiente:**p-[(1RS,2SR)-3-(p-fluorofenil)-2-hidroxi-1-(1H-1,2,4-triazol-1-il)propil]benzonitrilo*and enantiomer
et énantiomère
y enantiómero**p. 57 ibritumomabum tiuxetanum**

ibritumomab tiuxetan

*sustituyase la descripción por la siguiente:*inmunoglobulina G1, anti-(antígeno CD20 humano) (cadena γ 1 del anticuerpo monoclonal de ratón IDEC-Y2B8), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón IDEC-Y2B8, conjugada con N-[2-[bis(carboximetil)amino]-3-(4-isotiocianatofenil)propil]-N-[2-[bis(carboximetil)amino]propil]glicina**p. 67 sibrotuzumabum**

sibrotuzumab

*sustituyase la descripción por la siguiente:*inmunoglobulina G1, anti-(FAP (proteína de activación de los fibroblastos) humana) (cadena γ 1 del anticuerpo monoclonal humanizado de ratón BIBH1), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón BIBH1**p. 75 lintuzumabum**

lintuzumab

*sustituyase la descripción por la siguiente:*inmunoglobulina G1, anti-(antígeno CD33 humano) (cadena γ 1 del anticuerpo monoclonal humanizado de ratón HuM195), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón HuM195

Recommended International Nonproprietary Names (Prop. INN): List 44
Dénominations communes internationales recommandées (DCI Prop.): Liste 44
Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

- p. 202 **prinomastatum**
 prinomastat *replace the description by the following:*
 (S)-2,2-dimethyl-4-[[p-(4-pyridyloxy)phenyl]sulfonyl]-
 3-thiomorpholinecarbohydroxamic acid
- p. 202 **pumafentrinum**
 pumafentrina *sustituyase la descripción por la siguiente:*
 (-)-p-[(4aR*,10bS*)-9-etoxy-1,2,3,4,4a,10b-hexahidro-8-metoxi-
 2-metilbenzo[c][1,6]naftiridin-6-il]-N,N-diisopropilbenzamida

Recommended International Nonproprietary Names (Prop. INN): List 45
Dénominations communes internationales recommandées (DCI Prop.): Liste 45
Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 45
(WHO Drug Information, Vol. 15, No. 1, 2001)

- p. 54 *suprimase*
 olmesartán medoxmilo *insértese*
 olmesartán medoxmilo
- p. 33 **bevacizumabum**
 bevacizumab *sustituyase la descripción por la siguiente:*
 inmunoglobulina G1 anti-(factor de crecimiento del endotelio vascular humano) (cadena γ1 del anticuerpo monoclonal humanizado de ratón rhuMab-VEGF), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón rhuMab-VEGF
- p. 34 **bivatuzumabum**
 bivatuzumab *replace the description by the following:*
 immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer
- bivatuzumab *remplacer la description par la suivante:*
 immunoglobuline G1 anti (antigène CD44v6 humain) (chaîne γ1 de l'anticorps monoclonal de souris BIWA4 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BIWA4 humanisé
- bivatuzumab *sustituyase la descripción por la siguiente:*
 inmunoglobulina G1 anti-(antígeno humano CD44v6) (cadena γ1 del anticuerpo monoclonal humanizado de ratón BIWA4), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón BIWA4
- p. 40 **gadofosvesetum**
 gadofosveset *sustituyase la descripción por la siguiente:*
 trihidrogeno[2,2'-[[[(1R)-1-[[[2-[bis[(carboxi-κ-O)metil]amino-κ-N]etil][carboxi-κ-O)metil]amino-κ-N]etil]2-[[[(4,4,-difenilciclohexil)oxi]hidroxifosforil]=oxi]etil]imino-κ-N]diacetato(6-)-κ-O-κ-O']gadolinato(3-)

- p. 47 **ozogamicinum**
ozogamicina
- sustituyase la descripción por la siguiente:*
(1*R*,4*Z*,8*S*,13*E*)-13-[2-[[[*p*-(3-carbamoylpropoxy)- α -metilbencilideno]=hidrazino]carbonil]-1,1-dimetiletil]ditio]etilideno]-8-[[4,6-didesoxi-4-[[[2,6-didesoxi-4-*S*-[4-[(6-desoxi-3-*O*-metil- α -*L*-manopiranosil)oxi]-3-iodo-5,6-dimetoxi-*o*-toluolil]-4-tio- β -*D*-ribo-hexopiranosil]oxi]amino]-2-*O*-[2,4-didesoxi-4-(*N*-etilacetamido)-3-*O*-metil- α -*L*-treo-pentopiranosil]- β -*D*-glucopiranosil] oxi]-1-hidroxi-11-oxobiciclo[7.3.1]trideca-4,9-dieno-2,6-diino-10-carbamato de metilo
- p. 48 **pitavastatinum**
pitavastatina
- sustituyase la descripción por la siguiente:*
ácido (3*R*,5*S*,6*E*)-7-[2-ciclopropil-4-(*p*-fluorofenil)-3-quinolil]-3,5-dihidroxi-6-heptenoico

Recommended International Nonproprietary Names (Prop. INN): List 46
Dénominations communes internationales recommandées (DCI Prop.): Liste 46
Denominaciones Comunes Internacionales Recomendadas (DCI Prop.): Lista 46
(WHO Drug Information, Vol. 15, No. 3-4, 2001)

- p. 217 *supprimer*
lérdelimumab
- insérer*
lerdélimumab
- p. 192 **aviscuminum**
aviscumina
- sustituyase la descripción por la siguiente:*
toxina ML-I (lectina I de muérdago) (*Viscum album*) obtenida por ingeniería genética, constituida por dos cadenas peptídicas A (250 aminoácidos) y B (264 aminoácidos) unidas entre sí por un puente disulfuro
- p. 201 **imatinibum**
imatinib
- sustituyase la descripción por la siguiente:*
 α -(4-metil-1-piperazinil)-3'-[[4-(3-piridil)-2-pirimidinil]amino]-*p*-toluidida
- p. 201 **lemalesomabum**
lemalesomab
- sustituyase la descripción por la siguiente:*
immunoglobulina G1, anti (antígeno celular del granulocito humano NCA 90) (cadena γ 1 del anticuerpo monoclonal de ratón IMMUN MN3), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón IMMUN MN3
- p. 207 **pittrakinaurum**
pittrakina
- sustituyase la descripción por la siguiente:*
L-metionil-[121-ácido aspártico,124-ácido aspártico]interleukina-4
- p. 208 *suprimase*
pradofloxacina
- insértese*
pradofloxacino

p. 213 **tipifarnibum**

tipifarnib

*sustituyase la descripción por la siguiente:**(+)-6-[(R)-amino(4-clorofenil)(1-metil-1H-imidazol-5-il)metil]-4-(3-clorofenil)-1-metilquinolin-2(1H)-ona*p. 216 **zelandopamum**

zelandopam

*sustituyase la descripción por la siguiente:**(-)-(S)-4-(3,4-dihidroxifenil)-1,2,3,4-tetrahydro-7,8-isoquinolinadiol***Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.